Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Laura Reilly

Neurology Overland Park, KS Medical Doctor

NPI 1821023896 CMS profile 354547

10600 Mastin St, Overland Park, KS 66212

Open in the dashboard

General payments

$4,798

384 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Laura Reilly of Overland Park, KS is reported in the CMS Open Payments database as having received $4,798 across 384 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $17 1
2021 General $1,496 132
2020 General $1,672 116
2019 General $1,614 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Reilly
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Laura Reilly were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Laura Reilly Neurology median Middle half National median
2019 $1,614 $474 $118–$2,177 $163
2020 $1,672 $367 $82–$2,309 $114
2021 $1,496 $438 $104–$2,547 $132
2022 $17 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Teva Pharmaceuticals USA, Inc. $689 66 payments
  2. Upsher-Smith Laboratories LLC $492 33 payments
  3. Amgen Inc. $430 28 payments
  4. Lilly USA, LLC $420 31 payments
  5. AbbVie, Inc. $404 44 payments
  6. UCB, Inc. $331 22 payments
  7. Alexion Pharmaceuticals, Inc. $312 23 payments
  8. Zyla Life Sciences $299 30 payments
  9. Allergan Inc. $244 15 payments
  10. Novartis Pharmaceuticals Corporation $191 14 payments
  11. Other $985 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,794 383 payments
  2. Travel and Lodging $4 1 payment
Products named General payments · program years 2019–2022
  1. AIMOVIG $573 39 payments
  2. AJOVY $516 45 payments
  3. Zembrace SymTouch Sumatriptan Injection $321 19 payments
  4. EMGALITY $317 27 payments
  5. Soliris $312 23 payments
  6. Tosymra Sumatriptan Nasal Spray $310 18 payments
  7. SPRIX $299 30 payments
  8. UBRELVY $220 29 payments
  9. Briviact $206 14 payments
  10. NUPLAZID $180 12 payments
  11. Other $2,176 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

384 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record